In a cohort of 1134 patients with normal albumin at baseline undergoing surgical, locoregional or chemotherapy treatments for HCC, it was shown that patients taking BCAA with albumin 3.6–4.0 and with Stage III/IV disease had a longer OS compared to controls with the same stage and albumin levels. The gene discussed is ALB; the disease is hepatocellular carcinoma.